Publications:

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers

Sharma, Geeta Geeta GG; Mota, Ines I; Mologni, Luca L; Patrucco, Enrico E; Gambacorti-Passerini, Carlo C; Chiarle, Roberto R

Publication Date: 2018-02-28

Variant appearance in text: ALK: L256Q

PubMed Link: 29495603

Variant Present in the following documents:

• Main text

View BVdb publication page

The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.

Oncotarget

George, Suraj Konnath SK; Vishwamitra, Deeksha D; Manshouri, Roxsan R; Shi, Ping P; Amin, Hesham M HM

Publication Date: 2014-07-30

Variant appearance in text: ALK: L256Q

PubMed Link: 25026277

Variant Present in the following documents:

• Main text

View BVdb publication page